Boston Scientific Inc. said Wednesday the Food and Drug Administration approved several new implantable heart devices the company developed.
The company said the FDA approved its Incepta, Energen and Punctua devices. Incept and Punctua are implantable cardioverter defibrillators, which are used to treat rapid heartbeats. Energen is a cardiac resynchronization device, which includes an ICD and a resynchronization device used to coordinate the pumping of the heart.
The company says the devices are smaller and thinner than older heart implants, and that they are easier to implant and less visible from the outside. Boston Scientific said the first Incepta implant occurred Tuesday.
European regulators approved the Energen and Punctua product lines in October 2010, and they have been on sale in Europe and other non-U.S. markets since May.
Shares of Boston Scientific gained 17 cents, or 3.1 percent, to $5.72 as the markets rose in midday trading.